MedTrace Logo

A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine

NCT07753265 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-07

No results posted yet for this study

Summary

Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.

Conditions

  • Herpse Zoster

Interventions

BIOLOGICAL

live-attenuated zoster vaccine

one dose of live-attenuated zoster vaccine to the particpent only administered one dose of recombinant zoster vaccine

Sponsors & Collaborators

  • Changchun BCHT Biotechnology Co.

    lead INDUSTRY

Principal Investigators

  • yan shaohong · Inner Mongolia Autonomous Region Center for Disease Control and Prevention

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-13
Primary Completion
2026-09-20
Completion
2026-09-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07753265 on ClinicalTrials.gov